A senolysis-based theragnostic prodrug strategy towards chronic renal failure

Selective elimination of senescent cells (senolysis) has become a promising therapeutic strategy for the management of chronic renal failure (CRF), but the senolytic molecular pathways towards CRF therapy are limited. Here, we present for the first time a senescence-associated beta-galactosidase (SA-beta-gal) activatable theragnostic prodrug strategy to pertinently and effectively treat CRF in mice with the aid of fluorescence-guided senolysis. The signs of premature senescence, including the overexpression of beta-gal, have been found in kidneys of mice with CRF, making this enzyme particularly suitable as a trigger of prodrugs for CRF therapy. With this unique design, our pioneering prodrug TSPD achieved the activation of a fluorophore for tracking and the specific release of the parent drug, gemcitabine, in beta-gal-enriched cells after activation with SA-beta-gal. In mice with CRF, abdominal administration of TSPD was effective for improvement of the kidney functions, supporting the feasibility of the SA-beta-gal-dependent senolysis therapy towards CRF.

Automated summary

In this study, a therapeutic prodrug was designed to specifically treat chronic renal failure by using a senescence-associated enzyme as a trigger. The prodrug showed promising results in improving kidney function in mice with the disease.